Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

J&J’s Rybrevant Approval Adds a New Oncology Catalyst for Investors

Johnson & Johnson’s accelerated FDA approval for Rybrevant strengthens its oncology pipeline and puts regulatory execution back in focus.

Nov 6, 2026
Pharmaceutical

Xeris’ Recorlev Ambition Pulls Forward Revenue Case as XERS Nears Seven-Year Highs

Xeris’ earlier Recorlev sales ambition gives XERS a sharper growth narrative, but clinical milestones and execution risks remain.

Nov 5, 2026
Pharmaceutical

Viatris Stock Gains 1.6% as Q3 Results Put $19.51 Breakout in Focus

Viatris shares rose 1.6% after Q3 results, putting the $19.51 breakout level and prior FDA approval in focus for traders.

Nov 5, 2026
Pharmaceutical

ANI Pharmaceuticals’ $560 Million Egetis Deal Signals Renewed Rare-Disease M&A Momentum

ANI Pharmaceuticals’ reported $560 million Egetis acquisition would expand its rare-disease portfolio and underscore cross-border biotech co…

Nov 5, 2026
Pharmaceutical

Agenus Posts Q3 Profit as Phase 3 Colon Cancer Trial Moves Forward

Agenus reported a Q3 profit while advancing its Phase 3 colon cancer trial, giving investors a fresh catalyst to weigh ahead of 2027.

Nov 5, 2026
Pharmaceutical

Novavax Narrows Q3 Loss as Sanofi Partnership Delivers $125 Million Milestone

Novavax posted a $31 million Q3 loss as a Sanofi-linked milestone payment offset a 3% revenue decline to $68 million.

Nov 5, 2026
Pharmaceutical

Rhythm Pharmaceuticals Jumps on Reported $10 Billion AstraZeneca Bid

A reported $10 billion AstraZeneca bid sent Rhythm Pharmaceuticals shares higher and could reset expectations for rare-disease and metabolic…

Nov 5, 2026
Pharmaceutical

Rapport Therapeutics’ $815 Million Cash Position Sets Up a Catalyst-Heavy End to 2026

Rapport’s $815.4 million cash balance and coming epilepsy data put its Phase 3 program at the center of investor attention.

Nov 4, 2026
Pharmaceutical

Ultragenyx Faces a Gene-Therapy Growth Test After Two FDA Approvals and Workforce Cuts

Ultragenyx’s two FDA-approved gene therapies mark a commercial shift, but Q3 revenue of $173 million came with a $118 million net loss.

Nov 4, 2026
Pharmaceutical

GRAIL Stock Nears 52-Week High as FDA Panel Backs Cancer Detection Test Ahead of Earnings

GRAIL shares stand near their 52-week high as an FDA panel backs its cancer test and earnings approach, setting up two potential volatility …

Nov 4, 2026
Pharmaceutical

Compass Pathways Slides as Psychedelic Drug Race Raises Competitive Pressure

Compass Pathways faces renewed investor scrutiny as competition in the psychedelic-medicine approval race challenges first-mover assumptions…

Nov 4, 2026
Pharmaceutical

United Therapeutics Removes Pfizer Royalty Overhang Ahead of Ralinepag FDA Decision

United Therapeutics paid $525 million to eliminate a Pfizer royalty obligation as once-daily oral ralinepag remains under FDA review.

Nov 4, 2026